NewsRx

Search our medical news database

Antisense Technology

Small Cell Lung Cancer Study Begins for G3139

Published in Gene Therapy Weekly, January 27th, 2000

Genta Incorporated announced that the US National Cancer Institute (NCI) commenced a Phase 1-2 study of Genta's lead anticancer compound, G3139.

The study will use G3139 in combination with paclitaxel (Taxol(R), Bristol Myers Squibb) for the treatment of relapsed small cell lung cancer. About 25% of all lung cancers are the small cell type. While chemotherapy very often produces initial responses, the disease commonly relapses in less than a year. Following relapse, the available treatment options for patients are limited. The study is being conducted under the previously announced Cooperative Research and Development Agreement (CRADA) between Genta and the NCI. ...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook